Abstract

BackgroundDoxorubicin is one of the most effective anti-cancer drugs but its use is limited by cumulative cardiotoxicity that restricts lifetime dose. Redox damage is one of the most accepted mechanisms of toxicity, but not fully substantiated. Moreover doxorubicin is not an efficient redox cycling compound due to its low redox potential. Here we used genomic and chemical systems approaches in vivo to investigate the mechanisms of doxorubicin cardiotoxicity, and specifically test the hypothesis of redox cycling mediated cardiotoxicity.Methodology/Principal FindingsMice were treated with an acute dose of either doxorubicin (DOX) (15 mg/kg) or 2,3-dimethoxy-1,4-naphthoquinone (DMNQ) (25 mg/kg). DMNQ is a more efficient redox cycling agent than DOX but unlike DOX has limited ability to inhibit gene transcription and DNA replication. This allowed specific testing of the redox hypothesis for cardiotoxicity. An acute dose was used to avoid pathophysiological effects in the genomic analysis. However similar data were obtained with a chronic model, but are not specifically presented. All data are deposited in the Gene Expression Omnibus (GEO). Pathway and biochemical analysis of cardiac global gene transcription and mRNA translation data derived at time points from 5 min after an acute exposure in vivo showed a pronounced effect on electron transport chain activity. This led to loss of ATP, increased AMPK expression, mitochondrial genome amplification and activation of caspase 3. No data gathered with either compound indicated general redox damage, though site specific redox damage in mitochondria cannot be entirely discounted.Conclusions/SignificanceThese data indicate the major mechanism of doxorubicin cardiotoxicity is via damage or inhibition of the electron transport chain and not general redox stress. There is a rapid response at transcriptional and translational level of many of the genes coding for proteins of the electron transport chain complexes. Still though ATP loss occurs with activation caspase 3 and these events probably account for the heart damage.

Highlights

  • Doxorubicin (DOX), is one of the most widely used anticancer drugs for solid tumours, but its use is compromised by lifetime dose related cardiotoxicity [1]

  • A significant increase in the MB form of CK was measured from 5 min that continued to increase to 1 hr for both DOX and DMNQ (Figure 1D)

  • Plasma Troponin (TpI) was measured and a rapid increase observed after DMNQ maximal at the first time point measured (30 min.) that decreased at 12 hr after dosing

Read more

Summary

Introduction

Doxorubicin (DOX), is one of the most widely used anticancer drugs for solid tumours, but its use is compromised by lifetime dose related cardiotoxicity [1]. Overexpression of catalase decreases DOX toxicity supporting the redox hypothesis[10]. Co-administration of redox inhibitors and ROS scavengers does not ameliorate the cardiotoxicity in the clinic supporting the involvement of mechanisms other than, or in addition to, redox activity[16,17]. Doxorubicin is one of the most effective anti-cancer drugs but its use is limited by cumulative cardiotoxicity that restricts lifetime dose. We used genomic and chemical systems approaches in vivo to investigate the mechanisms of doxorubicin cardiotoxicity, and test the hypothesis of redox cycling mediated cardiotoxicity

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.